"The board is satisfied that there are no negative issues and trading remains in line with board expectations," the company said in a short statement.
Shares in the company were trading 8.6% lower at
Fri, 16th Mar 2018 16:21
"The board is satisfied that there are no negative issues and trading remains in line with board expectations," the company said in a short statement.
Shares in the company were trading 8.6% lower at
(ShareCast News) - AIM-listed regenerative medical devices company Tissue Regenix Group's saw operating losses widen at the interim stage even as its revenues nudged higher, although it did gain regulatory approval for its products in Europe and the US. For the six months ended 31 July, revenue incr
Read more(ShareCast News) - Regenerative medical device company Tissue Regenix released an update on two of its devices for a potential pilot study and product launch. The AIM listed company is currently undertaking clinical trials within the European Union for OrthoPure XT and OrthoPure XM products. The co
Read more(ShareCast News) - Tissue Regenix announced its first step towards the commercialisation of two of its products on Tuesday, through a joint venture agreement with a German tissue bank. The AIM-listed company said it had entered into an agreement with GTM-V to form a venture called GBM-V, a tissue ba
Read more